{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:50:53Z","timestamp":1781769053620,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04046-8","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T15:29:20Z","timestamp":1745508560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ruxolitinib stopped before transplantation does not induce cytokine release in myelofibrosis"],"prefix":"10.1007","volume":"74","author":[{"given":"Sara","family":"Villar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Curis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Schlageter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Bosselut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Turlure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9rome","family":"Cornillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Orvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Michonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Soci\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"4046_CR1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1186\/s12967-023-04393-z","volume":"21","author":"K Ghosh","year":"2023","unstructured":"Ghosh K, Shome DK, Kulkarni B, Ghosh MK, Ghosh K (2023) Fibrosis and bone marrow: understanding causation and pathobiology. J Transl Med 21:703","journal-title":"J Transl Med"},{"key":"4046_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799\u2013807","journal-title":"N Engl J Med"},{"key":"4046_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jtct.2022.01.018","volume":"28","author":"C Cipkar","year":"2022","unstructured":"Cipkar C, Kumar S, Thavorn K, Kekre N (2022) Optimal timing of allogeneic stem cell transplantation for primary myelofibrosis. Transplant Cell Ther 28:189\u2013194","journal-title":"Transplant Cell Ther"},{"key":"4046_CR4","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","volume":"133","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B et al (2019) Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood 133:2233\u20132242","journal-title":"Blood"},{"key":"4046_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.bbmt.2018.09.001","volume":"25","author":"V Gupta","year":"2019","unstructured":"Gupta V, Kosiorek HE, Mead A, Klisovic RB, Galvin JP, Berenzon D et al (2019) Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: myeloproliferative disorders research consortium 114 study. Biol Blood Marrow Transplant 25:256\u2013264","journal-title":"Biol Blood Marrow Transplant"},{"key":"4046_CR6","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/ajh.26279","volume":"96","author":"J-C Hern\u00e1ndez-Boluda","year":"2021","unstructured":"Hern\u00e1ndez-Boluda J-C, Pereira A, Kr\u00f6ger N, Cornelissen JJ, Finke J, Beelen D et al (2021) Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: a study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis registry. Am J Hematol 96:1186\u20131194","journal-title":"Am J Hematol"},{"key":"4046_CR7","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/s41409-021-01252-7","volume":"56","author":"M Robin","year":"2021","unstructured":"Robin M, Porcher R, Orvain C, Bay J-O, Barraco F, Huynh A et al (2021) Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups. Bone Marrow Transplant 56:1888\u20131899","journal-title":"Bone Marrow Transplant"},{"key":"4046_CR8","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. (1995) 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant, 15: 825\u2013828"},{"key":"4046_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.bbmt.2005.10.023","volume":"12","author":"HM Shulman","year":"2006","unstructured":"Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E et al (2006) Histopathologic diagnosis of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. pathology working group report. Biol Blood Marrow Transplant 12:31\u201347","journal-title":"Biol Blood Marrow Transplant"},{"key":"4046_CR10","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1182\/blood-2006-07-034348","volume":"109","author":"RM Saliba","year":"2007","unstructured":"Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C et al (2007) Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 109:2751\u20132758","journal-title":"Blood"},{"key":"4046_CR11","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.1182\/bloodadvances.2022007477","volume":"6","author":"M Robin","year":"2022","unstructured":"Robin M, Porcher R, Michonneau D, Taurines L, de Fontbrune FS, Xhaard A et al (2022) Prospective external validation of biomarkers to predict acute graft-versus-host disease severity. Blood Adv 6:4763\u20134772","journal-title":"Blood Adv"},{"key":"4046_CR12","unstructured":"R: The R Project for Statistical Computing. https:\/\/www.r-project.org\/. Accessed 13 Nov 2024"},{"key":"4046_CR13","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A (2011) Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 29:1356\u20131363","journal-title":"J Clin Oncol"},{"key":"4046_CR14","doi-asserted-by":"publisher","first-page":"107709","DOI":"10.1016\/j.pharmthera.2020.107709","volume":"219","author":"T Tang","year":"2021","unstructured":"Tang T, Cheng X, Truong B, Sun L, Yang X, Wang H (2021) Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint. Pharmacol Ther 219:107709","journal-title":"Pharmacol Ther"},{"key":"4046_CR15","doi-asserted-by":"publisher","first-page":"e000510","DOI":"10.1136\/esmoopen-2019-000510","volume":"4","author":"M Piechutta","year":"2019","unstructured":"Piechutta M, Berghoff AS (2019) New emerging targets in cancer immunotherapy: the role of cluster of differentiation 40 (CD40\/TNFR5). ESMO Open 4:e000510","journal-title":"ESMO Open"},{"key":"4046_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","volume":"41","author":"J Fu","year":"2023","unstructured":"Fu J, Wu H (2023) Structural mechanisms of NLRP3 inflammasome assembly and activation. Annu Rev Immunol 41:301\u2013316","journal-title":"Annu Rev Immunol"},{"key":"4046_CR17","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.3390\/jcm9082334","volume":"9","author":"L Longhitano","year":"2020","unstructured":"Longhitano L, Li Volti G, Giallongo C, Spampinato M, Barbagallo I, Di Rosa M et al (2020) The role of inflammation and inflammasome in myeloproliferative disease. J Clin Med 9:2334","journal-title":"J Clin Med"},{"key":"4046_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1186\/s12885-024-12301-x","volume":"24","author":"H Xiong","year":"2024","unstructured":"Xiong H, Zhang H, Bai J, Li Y, Li L, Zhang L (2024) Associations of the circulating levels of cytokines with the risk of myeloproliferative neoplasms: a bidirectional mendelian-randomization study. BMC Cancer 24:531","journal-title":"BMC Cancer"},{"key":"4046_CR19","doi-asserted-by":"publisher","first-page":"6702","DOI":"10.1182\/blood-2011-08-375006","volume":"118","author":"JLM Ferrara","year":"2011","unstructured":"Ferrara JLM, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T et al (2011) Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 118:6702\u20136708","journal-title":"Blood"},{"key":"4046_CR20","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2352-3026(14)00035-0","volume":"2","author":"JE Levine","year":"2015","unstructured":"Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H et al (2015) A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol 2:e21-29","journal-title":"Lancet Haematol"},{"key":"4046_CR21","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.1182\/bloodadvances.2019000791","volume":"3","author":"HK Srinagesh","year":"2019","unstructured":"Srinagesh HK, \u00d6zbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K et al (2019) The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv 3:4034\u20134042","journal-title":"Blood Adv"},{"key":"4046_CR22","doi-asserted-by":"publisher","first-page":"e89798","DOI":"10.1172\/jci.insight.89798","volume":"2","author":"MJ Hartwell","year":"2017","unstructured":"Hartwell MJ, \u00d6zbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P et al (2017) An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight 2:e89798","journal-title":"JCI Insight"},{"key":"4046_CR23","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1182\/blood-2012-01-403063","volume":"119","author":"JE Levine","year":"2012","unstructured":"Levine JE, Logan BR, Wu J, Alousi AM, Bola\u00f1os-Meade J, Ferrara JLM et al (2012) Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a blood and marrow transplant clinical trials network study. Blood 119:3854\u20133860","journal-title":"Blood"},{"key":"4046_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood-2008-07-167098","volume":"113","author":"S Paczesny","year":"2009","unstructured":"Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R et al (2009) A biomarker panel for acute graft-versus-host disease. Blood 113:273\u2013278","journal-title":"Blood"},{"key":"4046_CR25","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","volume":"24","author":"N Kr\u00f6ger","year":"2018","unstructured":"Kr\u00f6ger N, Abd Kadir SSS, Zabelina T, Badbaran A, Christopeit M, Ayuk F et al (2018) Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation. Biol Blood Marrow Transplant 24:2152\u20132156","journal-title":"Biol Blood Marrow Transplant"},{"key":"4046_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05703-1","author":"Z Wang","year":"2024","unstructured":"Wang Z, Jin X, Zeng J, Xiong Z, Chen X (2024) The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis. Ann Hematol. https:\/\/doi.org\/10.1007\/s00277-024-05703-1","journal-title":"Ann Hematol"},{"key":"4046_CR27","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/j.bbmt.2020.08.015","volume":"26","author":"U Ibrahim","year":"2020","unstructured":"Ibrahim U, Petrone GEM, Mascarenhas J, Keyzner A (2020) Peritransplantation use of ruxolitinib in myelofibrosis. Biol Blood Marrow Transplant 26:2177\u20132180","journal-title":"Biol Blood Marrow Transplant"},{"key":"4046_CR28","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1080\/10428190500126463","volume":"46","author":"JC Wang","year":"2005","unstructured":"Wang JC (2005) Importance of plasma matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinase (TIMP) in development of fibrosis in agnogenic myeloid metaplasia. Leuk Lymphoma 46:1261\u20131268","journal-title":"Leuk Lymphoma"},{"key":"4046_CR29","doi-asserted-by":"publisher","first-page":"e0252163","DOI":"10.1371\/journal.pone.0252163","volume":"16","author":"C-H Chang","year":"2021","unstructured":"Chang C-H, Lin Y-L, Tyan Y-S, Chiu Y-H, Liang Y-H, Chen C-P et al (2021) Interleukin-1\u03b2-induced matrix metalloproteinase-3 via ERK1\/2 pathway to promote mesenchymal stem cell migration. PLoS ONE 16:e0252163","journal-title":"PLoS ONE"},{"key":"4046_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/cells7070080","volume":"7","author":"A Malara","year":"2018","unstructured":"Malara A, Ligi D, Di Buduo CA, Mannello F, Balduini A (2018) Sub-cellular localization of metalloproteinases in megakaryocytes. Cells 7:80","journal-title":"Cells"},{"key":"4046_CR31","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1046\/j.1365-2141.2002.03874.x","volume":"119","author":"JC Wang","year":"2002","unstructured":"Wang JC, Novetsky A, Chen C, Novetsky AD (2002) Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis. Br J Haematol 119:709\u2013712","journal-title":"Br J Haematol"},{"key":"4046_CR32","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1182\/bloodadvances.2021005035","volume":"6","author":"H Ali","year":"2022","unstructured":"Ali H, Tsai N-C, Synold T, Mokhtari S, Tsia W, Palmer J et al (2022) Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Blood Adv 6:1444\u20131453","journal-title":"Blood Adv"},{"key":"4046_CR33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000506758","volume":"144","author":"EV Morozova","year":"2021","unstructured":"Morozova EV, Barabanshikova MV, Moiseev IS, Shakirova AI, Barhatov IM, Ushal IE et al (2021) A prospective pilot study of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and ruxolitinib in patients with myelofibrosis. Acta Haematol 144:158\u2013165","journal-title":"Acta Haematol"},{"key":"4046_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1182\/blood-2021-146330","volume":"138","author":"G Hobbs","year":"2021","unstructured":"Hobbs G, Kim HT, Bottoms AS, Byrne MT, Schroeder MA, Tamari R et al (2021) A phase II study of ruxolitinib pre-, during- and post-hematopoietic celltransplantation for patients with primary or secondary myelofibrosis. Blood 138:169","journal-title":"Blood"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04046-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04046-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04046-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:24:17Z","timestamp":1747661057000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04046-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["4046"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04046-8","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"181"}}